OZEMPIC Comprehensive Forecast on the Accelerating Market Growth for Type 2 Diabetes, Obesity, Chronic Kidney Disease, MASH, PAD, Alzheimer's Disease, Liver Cirrhosis, and Type 1 Diabetes Mellitus by 2034

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on OZEMPIC providing insights into the drug market landscape and market forecast of OZEMPIC upto 2034.

Are you interested in finding out the projected market size of OZEMPIC in 2034? OZEMPIC Market Forecast @ https://www.delveinsight.com/sample-request/ozempic-sale-forecast-and-market-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Factors Driving OZEMPIC Growth
1. Market Share Gains and New Patient Starts
• OZEMPIC continues to capture substantial market share across the type 2 diabetes and weight management segments.
• A significant rise in new patient starts, fueled by increasing physician confidence and strong patient demand, is driving prescription growth.
• Novo Nordisk's robust commercial strategy, direct-to-consumer campaigns, and healthcare provider education initiatives are further accelerating adoption.

2. Expansion across Key Indications
• Type 2 Diabetes: OZEMPIC remains one of the leading GLP-1 receptor agonists for glycemic control, with cardiovascular benefits adding to its value proposition.
• Obesity/Weight Management: Strong off-label and on-label use for weight management is expanding its patient base, supported by favorable real-world outcomes.
• Cardiovascular Risk Reduction: Demonstrated efficacy in reducing major adverse cardiovascular events is boosting adoption in high-risk populations.
• Pipeline Developments: Ongoing trials in Non-alcoholic Steatohepatitis (NASH), Alzheimer's disease, and heart failure suggest potential future indications that could broaden its market reach.

For More Information about OZEMPIC Market Report @ https://www.delveinsight.com/sample-request/ozempic-sale-forecast-and-market-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The OZEMPIC Market Report offers projected sales forecasts for OZEMPIC for indications until 2034, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.

OZEMPIC Drug Summary
OZEMPIC (semaglutide) injection 0.25 mg, 0.5 mg, 1.0 mg or 2.0 mg is a once-weekly GLP-1 RA indicated, along with diet and exercise, to improve blood sugar (glucose) in adults with type 2 diabetes and to reduce the risk of major CV events such as heart attack, stroke or death in adults with type 2 diabetes mellitus with known heart disease. OZEMPIC is the only GLP-1 RA indicated to reduce the risk of worsening kidney disease and risk of death from CV events in adults with type 2 diabetes and CKD. OZEMPIC is currently marketed in 72 countries, and 7 million people with type 2 diabetes are currently being treated with OZEMPIC worldwide. The report provides OZEMPIC's sales, growth barriers and drivers, post usage and approvals in multiple indications. OZEMPIC is in the Phase III stage of clinical development for the treatment of patients with Alzheimer's disease (NCT04777396) and Peripheral Arterial Disease (NCT04560998); in Phase II stage for Liver Cirrhosis (NCT03987451); and in Phase I stage for type 1 diabetes mellitus (NCT07087795).

OZEMPIC Market Recent Developments
• In September 2025, Novo Nordisk announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, OZEMPIC (once-weekly injectable semaglutide) was associated with a reduced risk of major adverse cardiovascular events such as a heart attack or stroke by 23%. The data span nearly 60,000 US Medicare patients (aged ≥66 years) living with type 2 diabetes, atherosclerotic cardiovascular disease (ASCVD) - a condition where fatty deposits build up in blood vessels, reducing blood flow and increasing the risk of heart attacks, strokes and related problems - and multiple health conditions. The results were presented at the European Association for the Study of Diabetes (EASD) 2025.
• In August 2025, Novo Nordisk announced the launch of a new offer that enables self-paying, eligible, type 2 diabetes patients access to authentic, FDA-approved OZEMPIC (semaglutide) for USD 499 per month, as part of the company's ongoing effort to explore new collaborations and approaches to improving access to authentic semaglutide medicines. This offer is available through multiple platforms to eligible patients with a prescription for OZEMPIC and aims to assist type 2 diabetes patients who may potentially face prices at or above wholesale cost that are uninsured or choose to self-pay.
• In June 2025, Novo Nordisk announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for an update of the OZEMPIC (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.

Do you want to know more information of this report? @ https://www.delveinsight.com/sample-request/ozempic-sale-forecast-and-market-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

What is OZEMPIC Prescribed for?
Ozempic is a prescription medication primarily used to treat Type 2 Diabetes in adults. It works as a GLP-1 receptor agonist, helping the body regulate blood sugar by stimulating insulin release, reducing the amount of glucose produced by the liver, and slowing the movement of food through the stomach. These actions help improve blood sugar control and may also lead to weight loss in some patients. In addition, Ozempic is prescribed to reduce the risk of major cardiovascular events such as heart attack or stroke in adults with type 2 diabetes who also have Cardiovascular Disease. The medication is typically administered as a once-weekly subcutaneous injection as part of a broader treatment plan that includes diet and exercise.

OZEMPIC Market Assessment
This report provides a detailed market assessment of OZEMPIC for Type 2 Diabetes, Obesity, Chronic Kidney Disease, MASH, PAD, Alzheimer's Disease, Liver Cirrhosis, and Type 1 Diabetes Mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2020 to 2034.

OZEMPIC Clinical Assessment
The report provides the clinical trials information of OZEMPIC for Type 2 Diabetes, Obesity, Chronic Kidney Disease, MASH, PAD, Alzheimer's Disease, Liver Cirrhosis, and Type 1 Diabetes Mellitus covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.

Do you know your drug's competitive positioning against OZEMPIC? OZEMPIC Drugs Insights- https://www.delveinsight.com/sample-request/ozempic-sale-forecast-and-market-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

OZEMPIC Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the OZEMPIC.

OZEMPIC Market Size in the US
A dedicated section of the report focuses on the expected market size of OZEMPIC for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Why you should buy OZEMPIC Market Report
• The report provides future market assessments for OZEMPIC for Type 2 Diabetes, Obesity, Chronic Kidney Disease, MASH, PAD, Alzheimer's Disease, Liver Cirrhosis, and Type 1 Diabetes Mellitus in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies.
• Leading OZEMPIC for Type 2 Diabetes, Obesity, Chronic Kidney Disease, MASH, PAD, Alzheimer's Disease, Liver Cirrhosis, and Type 1 Diabetes Mellitus forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the OZEMPIC
• Discover the competitive landscape of OZEMPIC through 7MM
• Get a Thorough Analysis of the OZEMPIC Development pipeline, Safety & Efficacy of the OZEMPIC, and ROA
• Thorough OZEMPIC market forecast will help understand how drug is competing with other emerging OZEMPIC
• Get analysis of the OZEMPIC clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.